Celltrion, Hospira avoid biosimilar traffic jam in U.S.

With an FDA advisory committee meeting approaching on March 17 for CT-P13 from Celltrion Inc. (KOSDAQ:068270) and Hospira Inc. (NYSE:HSP), the partners' U.S. interests are aligned thanks

Read the full 271 word article

How to gain access

Continue reading with a
two-week free trial.